tiprankstipranks
Trending News
More News >
Novartis (CH:NOVN)
:NOVN
Switzerland Market
Advertisement

Novartis AG (NOVN) Stock Forecast & Price Target

Compare
18 Followers
See the Price Targets and Ratings of:

NOVN Analyst Ratings

Moderate Buy
12Ratings
Moderate Buy
5 Buy
6 Hold
1 Sell
Based on 12 analysts giving stock ratings to
Novartis
AG
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NOVN Stock 12 Month Forecast

Average Price Target

CHF101.90
▲(6.74% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Novartis AG in the last 3 months. The average price target is CHF101.90 with a high forecast of CHF115.00 and a low forecast of CHF89.00. The average price target represents a 6.74% change from the last price of CHF95.47.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"CHF84","92":"CHF92","100":"CHF100","108":"CHF108","116":"CHF116"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF101.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF89.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,92,100,108,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.19,95.79076923076923,97.39153846153846,98.99230769230769,100.59307692307692,102.19384615384615,103.79461538461538,105.39538461538461,106.99615384615385,108.59692307692308,110.19769230769231,111.79846153846154,113.39923076923077,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.19,94.78307692307692,95.37615384615384,95.96923076923076,96.5623076923077,97.15538461538462,97.74846153846154,98.34153846153846,98.93461538461538,99.5276923076923,100.12076923076924,100.71384615384616,101.30692307692308,{"y":101.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.19,93.79076923076923,93.39153846153846,92.99230769230769,92.59307692307692,92.19384615384615,91.79461538461538,91.39538461538461,90.99615384615385,90.59692307692308,90.19769230769231,89.79846153846154,89.39923076923077,{"y":89,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.15,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.92,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.29,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF115.00Average Price TargetCHF101.90Lowest Price TargetCHF89.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CH:NOVN
TipRanks AITipRanks
Not Ranked
TipRanks
CHF105
Buy
9.98%
Upside
Reiterated
08/07/25
Novartis AG's strong financial performance and positive earnings call are the most significant factors contributing to its score. The company's robust sales growth, upgraded guidance, and promising pipeline developments are major strengths. Technical indicators suggest a bearish trend, which slightly offsets the positive outlook. The valuation is reasonable, providing a decent return to investors.
Bernstein
CHF115CHF108
Buy
13.12%
Upside
Reiterated
08/04/25
Bernstein Sticks to Its Buy Rating for Novartis AG (NOVN)
Berenberg Bank Analyst forecast on CH:NOVN
Kerry HolfordBerenberg Bank
Berenberg Bank
CHF89
Hold
-6.78%
Downside
Reiterated
07/22/25
Novartis AG (NOVN) Receives a Hold from Berenberg Bank
UBS
CHF104CHF95
Hold
-0.49%
Downside
Reiterated
07/22/25
UBS Sticks to Its Hold Rating for Novartis AG (NOVN)
Barclays Analyst forecast on CH:NOVN
Emily FieldBarclays
Barclays
CHF90
Sell
-5.73%
Downside
Reiterated
07/21/25
Deutsche Bank  Analyst forecast on CH:NOVN
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
CHF115
Buy
20.46%
Upside
Reiterated
07/18/25
Novartis AG (NOVN) Gets a Buy from Deutsche Bank
DZ BANK AG Analyst forecast on CH:NOVN
Elmar KrausDZ BANK AG
DZ BANK AG
Buy
Reiterated
07/18/25
Novartis AG (NOVN) Gets a Buy from DZ BANK AG
J.P. Morgan Analyst forecast on CH:NOVN
Richard VosserJ.P. Morgan
J.P. Morgan
CHF95
Hold
-0.49%
Downside
Reiterated
07/18/25
Novartis AG (NOVN) Gets a Hold from J.P. Morgan
Jefferies
CHF100
Hold
4.74%
Upside
Reiterated
07/17/25
Novartis AG (NOVN) Gets a Hold from Jefferies
Bank of America Securities Analyst forecast on CH:NOVN
Sachin JainBank of America Securities
Bank of America Securities
CHF111
Hold
16.27%
Upside
Reiterated
07/17/25
Kepler Capital  Analyst forecast on CH:NOVN
David EvansKepler Capital
Kepler Capital
CHF106
Buy
11.03%
Upside
Reiterated
07/17/25
Kepler Capital Sticks to Their Buy Rating for Novartis AG (NOVN)
Goldman Sachs Analyst forecast on CH:NOVN
James QuigleyGoldman Sachs
Goldman Sachs
Hold
Reiterated
07/17/25
Goldman Sachs Reaffirms Their Hold Rating on Novartis AG (NOVN)
Exane BNP Paribas Analyst forecast on CH:NOVN
Peter VerdultExane BNP Paribas
Exane BNP Paribas
CHF95
Buy
-0.49%
Downside
Initiated
04/16/25
BNP Paribas Exane Starts Novartis (NOVN:SW) (NVS) at OutperformBNP Paribas Exane analyst Peter Verdult initiates coverage on Novartis (NOVN:SW) (NYSE: NVS) with a Outperform rating and a price target of CHF95.00.
Morgan Stanley Analyst forecast on CH:NOVN
Thibault BoutherinMorgan Stanley
Morgan Stanley
CHF91
Sell
-4.68%
Downside
Initiated
02/12/25
Novartis initiated with an Underweight at Morgan StanleyNovartis initiated with an Underweight at Morgan Stanley
Stifel Nicolaus Analyst forecast on CH:NOVN
Eric Le BerrigaudStifel Nicolaus
Stifel Nicolaus
CHF109
Hold
14.17%
Upside
Reiterated
01/31/25
Novartis AG: Balancing Strong Performance with Future Challenges - Hold Rating Maintained
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CH:NOVN
TipRanks AITipRanks
Not Ranked
TipRanks
CHF105
Buy
9.98%
Upside
Reiterated
08/07/25
Novartis AG's strong financial performance and positive earnings call are the most significant factors contributing to its score. The company's robust sales growth, upgraded guidance, and promising pipeline developments are major strengths. Technical indicators suggest a bearish trend, which slightly offsets the positive outlook. The valuation is reasonable, providing a decent return to investors.
Bernstein
CHF115CHF108
Buy
13.12%
Upside
Reiterated
08/04/25
Bernstein Sticks to Its Buy Rating for Novartis AG (NOVN)
Berenberg Bank Analyst forecast on CH:NOVN
Kerry HolfordBerenberg Bank
Berenberg Bank
CHF89
Hold
-6.78%
Downside
Reiterated
07/22/25
Novartis AG (NOVN) Receives a Hold from Berenberg Bank
UBS
CHF104CHF95
Hold
-0.49%
Downside
Reiterated
07/22/25
UBS Sticks to Its Hold Rating for Novartis AG (NOVN)
Barclays Analyst forecast on CH:NOVN
Emily FieldBarclays
Barclays
CHF90
Sell
-5.73%
Downside
Reiterated
07/21/25
Deutsche Bank  Analyst forecast on CH:NOVN
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
CHF115
Buy
20.46%
Upside
Reiterated
07/18/25
Novartis AG (NOVN) Gets a Buy from Deutsche Bank
DZ BANK AG Analyst forecast on CH:NOVN
Elmar KrausDZ BANK AG
DZ BANK AG
Buy
Reiterated
07/18/25
Novartis AG (NOVN) Gets a Buy from DZ BANK AG
J.P. Morgan Analyst forecast on CH:NOVN
Richard VosserJ.P. Morgan
J.P. Morgan
CHF95
Hold
-0.49%
Downside
Reiterated
07/18/25
Novartis AG (NOVN) Gets a Hold from J.P. Morgan
Jefferies
CHF100
Hold
4.74%
Upside
Reiterated
07/17/25
Novartis AG (NOVN) Gets a Hold from Jefferies
Bank of America Securities Analyst forecast on CH:NOVN
Sachin JainBank of America Securities
Bank of America Securities
CHF111
Hold
16.27%
Upside
Reiterated
07/17/25
Kepler Capital  Analyst forecast on CH:NOVN
David EvansKepler Capital
Kepler Capital
CHF106
Buy
11.03%
Upside
Reiterated
07/17/25
Kepler Capital Sticks to Their Buy Rating for Novartis AG (NOVN)
Goldman Sachs Analyst forecast on CH:NOVN
James QuigleyGoldman Sachs
Goldman Sachs
Hold
Reiterated
07/17/25
Goldman Sachs Reaffirms Their Hold Rating on Novartis AG (NOVN)
Exane BNP Paribas Analyst forecast on CH:NOVN
Peter VerdultExane BNP Paribas
Exane BNP Paribas
CHF95
Buy
-0.49%
Downside
Initiated
04/16/25
BNP Paribas Exane Starts Novartis (NOVN:SW) (NVS) at OutperformBNP Paribas Exane analyst Peter Verdult initiates coverage on Novartis (NOVN:SW) (NYSE: NVS) with a Outperform rating and a price target of CHF95.00.
Morgan Stanley Analyst forecast on CH:NOVN
Thibault BoutherinMorgan Stanley
Morgan Stanley
CHF91
Sell
-4.68%
Downside
Initiated
02/12/25
Novartis initiated with an Underweight at Morgan StanleyNovartis initiated with an Underweight at Morgan Stanley
Stifel Nicolaus Analyst forecast on CH:NOVN
Eric Le BerrigaudStifel Nicolaus
Stifel Nicolaus
CHF109
Hold
14.17%
Upside
Reiterated
01/31/25
Novartis AG: Balancing Strong Performance with Future Challenges - Hold Rating Maintained
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis AG

1 Month
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+0.99%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +0.99% per trade.
3 Months
xxx
Success Rate
17/25 ratings generated profit
68%
Average Return
+2.92%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.00% of your transactions generating a profit, with an average return of +2.92% per trade.
1 Year
David EvansKepler Capital
Success Rate
20/25 ratings generated profit
80%
Average Return
+9.04%
reiterated a buy rating 22 days ago
Copying David Evans's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +9.04% per trade.
2 Years
xxx
Success Rate
19/25 ratings generated profit
76%
Average Return
+11.86%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 76.00% of your transactions generating a profit, with an average return of +11.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOVN Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
21
22
20
20
15
Hold
17
14
18
20
16
Sell
3
3
3
4
2
Strong Sell
0
0
0
0
0
total
41
39
41
44
33
In the current month, NOVN has received 15 Buy Ratings, 16 Hold Ratings, and 2 Sell Ratings. NOVN average Analyst price target in the past 3 months is 101.90.
Each month's total comprises the sum of three months' worth of ratings.

NOVN Financial Forecast

NOVN Earnings Forecast

Next quarter’s earnings estimate for NOVN is CHF1.78 with a range of CHF1.70 to CHF1.87. The previous quarter’s EPS was CHF1.92. NOVN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year NOVN has Outperformed its overall industry.
Next quarter’s earnings estimate for NOVN is CHF1.78 with a range of CHF1.70 to CHF1.87. The previous quarter’s EPS was CHF1.92. NOVN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year NOVN has Outperformed its overall industry.

NOVN Sales Forecast

Next quarter’s sales forecast for NOVN is CHF10.93B with a range of CHF10.62B to CHF11.38B. The previous quarter’s sales results were CHF11.61B. NOVN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year NOVN has Outperformed its overall industry.
Next quarter’s sales forecast for NOVN is CHF10.93B with a range of CHF10.62B to CHF11.38B. The previous quarter’s sales results were CHF11.61B. NOVN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year NOVN has Outperformed its overall industry.

NOVN Stock Forecast FAQ

What is CH:NOVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Novartis’s 12-month average price target is 101.90.
    What is CH:NOVN’s upside potential, based on the analysts’ average price target?
    Novartis has 6.74% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Novartis a Buy, Sell or Hold?
          Novartis has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 6 hold ratings and 1 sell ratings.
            What is Novartis’s share price target?
            The average share price target for Novartis is 101.90. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF115.00 ,and the lowest forecast is CHF89.00. The average share price target represents 6.74% Increase from the current price of CHF95.47.
              What do analysts say about Novartis?
              Novartis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Novartis?
                To buy shares of CH:NOVN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis